GlassScriptPhysician profile
Eve A Knapp
NPI 1013095033
$8,570.62
in general payments reported to CMS, 2019-2025
61 companies · $1,546 in 2025
The $1,546 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $1,073 · 2021: $1,247 · 2022: $1,111 · 2023: $1,219 · 2024: $1,523 · 2025: $1,546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,288.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,119.35 | 2019-2025 | Biktarvy |
| Astrazeneca Pharmaceuticals LP | $753.45 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $676.89 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $602.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $560.32 | 2019-2025 | Evenity, Prolia, Repatha |
| Viiv Healthcare Company | $413.02 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Abbvie INC. | $408.51 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.94 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $351.19 | 2019-2025 | |
| Glaxosmithkline, LLC. | $299.88 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $281.99 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $240.19 | 2020-2025 | Isentress, Delstrigo, Pifeltro |
| Takeda Pharmaceuticals U.S.A., INC. | $209.53 | 2019-2025 | Trintellix |
| Astellas Pharma US INC | $196.09 | 2020-2024 | Veozah |
| Exact Sciences Corporation | $165.36 | 2023-2025 | Cologuard Collection Kit |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eve Knapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.